Business
Updated: GSK announces $30bn U.S. investment amid Trump visit to U.K
Britain’s GlaxoSmithKline (GSK) has announced a $30 billion investment in the United States.
The pharmaceutical giant said on Wednesday that the new funding will be channelled into research and development (R&D), advanced manufacturing, and digital technologies over the next five years.
The announcement coincided with President Donald Trump’s state visit to the U.K., which has been accompanied by a flurry of transatlantic investment pledges.
GSK revealed that $1.2 billion of the package will support advanced manufacturing and artificial intelligence, including the construction of a biologics plant in Pennsylvania for respiratory and cancer medicines, alongside digital upgrades to its existing facilities in Pennsylvania, North Carolina, Maryland, and Montana.
“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both,” GSK CEO Emma Walmsley said. “Today, we are committing to invest at least $30 billion in the United States over the next five years, further bolstering the already strong R&D and supply chain we have in the country.”
Trump’s visit has amplified this trend, with technology and healthcare giants, including Microsoft, Nvidia, Google, OpenAI, and Salesforce, announcing multibillion-dollar investments in the U.K. and U.S., signalling closer economic ties between Washington and London.
Editor’s Note
This story has been corrected and its original title, “After Quitting Nigeria, GSK Shifts Focus with $30bn U.S. Investment During Trump Visit,” adjusted because it contained inaccurate information.
GSK has informed us that contrary to the impression created in the report, the company has not exited Nigeria. In 2024, GSK transitioned to a new business model under which its products continue to be available in Nigeria through a major local distribution partner with a proven track record in serving patients in Nigeria and other African markets.
We regret the earlier misrepresentation and are pleased to make this correction in line with our commitment to accuracy and fairness.
